Indivior's Quarterly Profit Hits Record $137 Million Days Before Supernus Merger Is Set To Close
Sublocade sales rose 22% to $267 million and operating costs fell, in the drugmaker's last quarter as a standalone company.
Indivior, which develops prescription medicines for opioid use disorder, reported a record $137 million third-quarter net income, or $1.12 per diluted share, up from $42 million, or $0.33, a year earlier. The company said Thursday it is on track to close its all-stock merger with Supernus on November 2.
Sublocade drives a record quarter
Total net revenue rose 13% to $356 million from $314 million. Sublocade, the company's long-acting injectable for opioid use disorder, grew 22% to $267 million from $219 million.
U.S. Sublocade revenue climbed 24% to $252 million, primarily on 17% growth in dispense unit volume, the company said. Price/mix and gross-to-net adjustments also helped. More than 583,000 patients in the U.S. had been prescribed Sublocade since launch as of September 30.
Adjusted EBITDA, earnings before interest, taxes and certain other costs, rose 76% to $211 million from $120 million, a 59% margin. Non-GAAP net income, the company's adjusted measure, reached a record $161 million, or $1.32 per diluted share.
Operating costs drop by a third
Standard-accounting operating expenses fell 33% to $125 million from $187 million. Research and development spending shrank to $5 million from $33 million, and interest expense dropped to $2 million from $12 million.
For the first nine months, net revenue was $1,016 million, up 15%, and net income was $348 million against $108 million a year earlier. Cash and investments stood at $332 million at quarter end.
Last report before the Supernus deal
Indivior and Supernus announced the merger of equals in August, and Indivior shareholders approved it in October. The combined company will operate as Supernus and is set to trade on the Nasdaq Global Select Market as SUPN starting November 3. A special cash dividend contingent on closing was declared in September.
Indivior said it is on track for its 2026 guidance as a standalone company: net revenue of $1,295 million to $1,365 million and adjusted EBITDA of $700 million to $740 million. That guidance no longer applies once the merger closes.
CEO Joe Ciaffoni said the closing will complete all three phases of the Indivior Action Agenda, the company's turnaround program.
The merger is expected to close Monday, and the combined company begins trading as SUPN on Tuesday, November 3.
Sources
- 8-K Filing — Indivior Pharmaceuticals, Inc. (INDV) — SEC EDGAR
- Exhibit d169609dex991.htm — Indivior Pharmaceuticals, Inc. 8-K exhibit — SEC EDGAR